Balovaptan

Balovaptan (INN; developmental code name RG7314), is a selective small molecule antagonist of the vasopressin V1A receptor which is under development by Roche for the treatment of autism.[1] As of August 2019, it is in a phase III clinical trial for adults and a phase II clinical trial for children for this indication.[2] On 29 January 2018, Roche announced that the US Food and Drug Administration (FDA) had granted Breakthrough Therapy Designation for balovaptan in individuals with autism spectrum disorder (ASD).[3] The FDA granted this based on the results of the adult phase II clinical trial called VANILLA (Vasopressin ANtagonist to Improve sociaL communication in Autism) study.[3] The currently recruiting phase III adult study is called V1aduct and the currently closed out phase II child study is called Av1ation.

Balovaptan
Clinical data
Other namesRG7314
Legal status
Legal status
Identifiers
CAS Number
PubChem CID
DrugBank
ChemSpider
UNII
KEGG
Chemical and physical data
FormulaC22H24ClN5O
Molar mass409.92 g·mol−1
3D model (JSmol)

See also

References
  1. "Roche - Pipeline". 2014. Retrieved 1 August 2014.
  2. A Study of RG7314 to Investigate Efficacy and Safety in Individuals With Autism Spectrum Disorders, at ClinicalTrials.gov; retrieved 6 February 2018
  3. "FDA grants Breakthrough Therapy Designation for Roche's balovaptan in autism spectrum disorder" (Press release). 29 January 2018. Retrieved 6 February 2018.
  • "Balovaptan". Drug Information Portal. U.S. National Library of Medicine.


This article is issued from Wikipedia. The text is licensed under Creative Commons - Attribution - Sharealike. Additional terms may apply for the media files.